{"id":7446,"date":"2021-12-16T08:00:29","date_gmt":"2021-12-16T13:00:29","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/lanreotidacetat-cas-127984-74-1-behandling-for-akromegali-och-symtomatiska-neuroendokrina-tumorer\/"},"modified":"2021-12-16T08:00:29","modified_gmt":"2021-12-16T13:00:29","slug":"lanreotidacetat-cas-127984-74-1-behandling-for-akromegali-och-symtomatiska-neuroendokrina-tumorer","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/sv\/product\/lanreotidacetat-cas-127984-74-1-behandling-for-akromegali-och-symtomatiska-neuroendokrina-tumorer\/","title":{"rendered":"Lanreotidacetat CAS 127984-74-1 Behandling f\u00f6r akromegali och symtomatiska neuroendokrina tum\u00f6rer"},"content":{"rendered":"

Lanreotidacetat CAS 127984-74-1 Behandling f\u00f6r akromegali och symtomatiska neuroendokrina tum\u00f6rer<\/strong><\/h2>\n

Produktnamn: Lanreotidacetat
\nSynonymer: 10-(4-aminobutyl)-19-[(2-amino-3-naftalen-2-yl-propanoyl)amino]-N-(1-karbamoyl-2) -hydroxi-propyl)-16-[(4-hydroxifenyl)metyl]-13-(lH-indol-3-ylmetyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1 ,2-ditia-5,8,11,14,17-pentazacykloikosan-4-karboxamid;Somatulina;LANREOTIDACETAT;3-(2-naftalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptofyl- L-lysyl-L-valyl-L-cysteinyl-L-treoninamid cyklisk (2\u21927)-disulfidacetat; angiopeptinacetat; 10-(4-aminobutyl)-N-(1-amino-3-hydroxi-1-oxobutan -2-yl)-19-[(2-amino-3-naftalen-2-ylpropanoyl)amino]-16-[(4-hydroxifenyl)metyl]-13-(lH-indol-3-ylmetyl)-6, 9,12,15,18-pentaoxo-7-propan-2-yl-1,2-ditia-5,8,11,14,17-pentazacykloikosan-4-karboxamid; Lanreotidacetat USP\/EP\/BP
\n CAS: 127984-74-1
\nMF: C54H69N11O10S2
\nMW: 0
\nEINECS:
\nProduktkategorier: Aminosyror och derivat, l\u00e4kemedel, mellanprodukter och derivat
\nMol fil: 127984-74 1.mol<\/p>\n

Lanreotidacetat, ett oktapeptid somatostatin analog, n\u00e5dde sin f\u00f6rsta v\u00e4rldsomsp\u00e4nnande marknad i Frankrike f\u00f6r akromegali n\u00e4r kirurgi eller str\u00e5lbehandling har misslyckats med att \u00e5terst\u00e4lla normal uts\u00f6ndring av tillv\u00e4xthormon. Lanreotid \u00e4r en selektiv h\u00e4mmare av tillv\u00e4xthormon och minskar uts\u00f6ndringen av tillv\u00e4xthormon, tyrotropin, motilin och pankreaspolypeptid hos m\u00e4nniskor. Lanreotid har antiproliferativa egenskaper och rapporteras vara i kliniska pr\u00f6vningar f\u00f6r att f\u00f6rebygga restenos efter kransart\u00e4rangioplastik, f\u00f6r diabetisk retinopati och som en terapi f\u00f6r psoriasis. Dess potential f\u00f6r neuroendokrina tum\u00f6rer och hormonresponsiv prostatacancer har ocks\u00e5 visats.<\/p>\n

Lanreotide Acetate CAS 127984-74-1 Kemiska egenskaper<\/strong>
\nlagringstemperatur. -20\u00b0C
\nform pulver
\nf\u00e4rg vit till benvit<\/p>\n

Funktion och till\u00e4mpning av Lanreotidacetat CAS 127984-74-1<\/strong>
\nLanreotidacetat, liksom naturliga tillv\u00e4xth\u00e4mmare, \u00e4r lanreotid en peptidh\u00e4mmare av m\u00e5nga endokrina, neuroendokrina, exokrina och parakrina funktioner. Lanreotid \u00e4r mer aktivt och har en l\u00e4ngre verkningstid \u00e4n naturliga tillv\u00e4xth\u00e4mmare. Dess h\u00e4mmande effekt p\u00e5 uts\u00f6ndring av tillv\u00e4xthormon \u00e4r betydligt mer selektiv \u00e4n p\u00e5 insulinuts\u00f6ndring, och 2017 godk\u00e4nde FDA lanreotidacetat f\u00f6r injektion f\u00f6r behandling av neuroendokrina tum\u00f6rer.<\/p>\n","protected":false},"excerpt":{"rendered":"

Produktnamn: Lanreotide Acetate
\nCAS: 127984-74-1
\nMF: C54H69N11O10S2
\nMol Fil: 127984-74-1.mol<\/p>\n","protected":false},"featured_media":2112,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[384],"product_tag":[2298],"class_list":{"0":"post-7446","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-tumor-peptid","7":"product_tag-lanreotide-acetate-cas-127984-74-1-treat-for-acromegaly-and-symptomatic-neuroendocrine-tumors-sv","8":"desktop-align-left","9":"tablet-align-left","10":"mobile-align-left","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product\/7446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/comments?post=7446"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/media\/2112"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/media?parent=7446"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product_brand?post=7446"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product_cat?post=7446"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/sv\/wp-json\/wp\/v2\/product_tag?post=7446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}